Vaxcyte Pushes Next-Gen Pneumococcal Vaccine Into Phase 3 Phase - Vaxcyte (NASDAQ:PCVX)

Vaxcyte Pushes Next-Gen Pneumococcal Vaccine Into Phase 3 Phase - Vaxcyte (NASDAQ:PCVX)

Vaxcyte, Inc. (NASDAQ:PCVX), with a market capitalization of around $7 billion, is trading higher on Friday. The stock’s positive movement comes as Vaxcyte is advancing its VAX-31 vaccine trials across adult and infant programs, which could position it as a leader in pneumococcal disease prevention. VAX-31 is the company’s next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate. Vaxcyte Initiates Phase 3 VAX-31 Trials Vaxcyte on…

Vaxcyte, Inc. (NASDAQ:PCVX) Receives $101.17 Average PT from Brokerages

Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a […]